Fenghan granules and decoction for patients with post-infectious cough: a randomized controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072797

Enrollment

Unknown

Registered

2023-06-25

Start date

2023-07-01

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-infectious cough

Interventions

Medicinal granules group:Fenghan granules

Decoction group:Fenghan decoction

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)Aged between 18 and 65 years; (2)Diagnostic criteria meet the criteria of post-infection cough; (3)Diagnostic criteria meet theTCM syndrome differentiation of wind cold attacking the lung pattern; (4)Daytime cough symptoms are scored = 2 points or nighttime cough symptoms are scored = 2 points; (5)Sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patient with chronic respiratory disease, such as bronchial asthma, chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease, chronic sinusitis, chronic pharyngitis, or gastroesophageal reflux; (2) Patient with symptoms such as postnasal drip or acid reflux, stomach pain for 1 month; (3) Patient with serious diseases of cardiovascular and cerebrovascular, liver, kidney and hematopoietic system; (4) ALT and AST > 1.5 times upper limit of normal value, or serum creatinine (Scr) > 1.5 times upper limit of normal value; (5) The white blood cell count > 12×109/L and the proportion of neutrophils is higher than the upper limit of normal, or the white blood cell count is < 5.0×109/L; (6) Psychopaths; (7) Patients who smoke, or quit smoking for less than 6 months; (8) Taking ACEI drugs in the past 1 month; (9) Women planning pregnancy or pregnant or lactating women; (10) Those who have participated in or are currently participating in other clinical trials within 3 months.

Design outcomes

Primary

Measure	Time frame
Cough symptom score;	—

Secondary

Measure	Time frame
Days of cough relief;TCM symptom efficacy score;Cough sensitivity;Leicester cough quality of life questionnaire;Cough recurrence rate;Frequency of emergency drug use;	—

Countries

China

Contacts

Public ContactLei Wu

Guangdong Provincial Hospital of Chinese Medicine

drleiwu@163.com+86 137 9437 4910

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026